C12N 2760/20221
Viruses as such
Official title: Viruses as such, e.g. new isolates, mutants or their genomic sequences
C12N2760/20221 (Viruses as such) appears on 23 US grants and 50 published applications in this corpus.
Search patents in C12N- Granted patents
- 23
- Published applications
- 50
- Assignees
- 19
- Inventors
- 97
- Latest grant
- 4 Aug 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2003 | 0 | 1 |
| 2004 | 0 | 0 |
| 2005 | 0 | 0 |
| 2006 | 0 | 1 |
| 2007 | 0 | 0 |
| 2008 | 0 | 0 |
| 2009 | 0 | 0 |
| 2010 | 0 | 0 |
| 2011 | 1 | 1 |
| 2012 | 0 | 0 |
| 2013 | 1 | 1 |
| 2014 | 0 | 3 |
| 2015 | 0 | 1 |
| 2016 | 0 | 0 |
| 2017 | 6 | 7 |
| 2018 | 2 | 2 |
| 2019 | 0 | 1 |
| 2020 | 2 | 5 |
| 2021 | 0 | 3 |
| 2022 | 1 | 3 |
| 2023 | 4 | 5 |
| 2024 | 0 | 6 |
| 2025 | 5 | 5 |
| 2026 | 1 | 5 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Methods and materials for treating cancer4 Aug 2026US 12,697,361 B2Mayo Foundation for Medical Education and Research
- Oncolytic virus vaccine and drug for treating tumors by combining oncolytic virus vaccine with immune cells16 Dec 2025US 12,496,337 B2Joint Biosciences (Sh) Ltd.
- Recombinant rhabdovirus encoding for CCL2128 Oct 2025US 12,453,749 B2Boehringer Ingelheim International GmbH
- Recombinant oncolytic viruses for treatment of metastatic cancers5 Aug 2025US 12,378,289 B2Entos Pharmaceuticals Inc.
- Chimeric vesiculoviruses and methods of use27 May 2025US 12,311,000 B2Mayo Foundation for Medical Education and Research
- Method of producing negative-strand rna virus vector and produced negative-strand rna virus vector27 Aug 2026US 2026/0250709 A1Repli-Tech Co., Ltd.
- Recombinant oncolytic virus and use thereof16 Jul 2026US 2026/0199415 A1Joint Biosciences (Sh) Ltd.
- Recombinant rhabdovirus encoding for a gasdermin30 Apr 2026US 2026/0117200 A1Boehringer Ingelheim International GmbH
- Process for producing a purified rhabdovirus from cell culture26 Mar 2026US 2026/0085294 A1Boehringer Ingelheim International GmbH
- Method for treating tumors using combination of oncolytic virus vaccine and immune cells15 Jan 2026US 2026/0014238 A1Joint Biosciences (Sh) Ltd.
Most cited
By later US patents
- Recombinant vesicular stomatitis virus vaccines for viral hemorrhagic fevers7US 8,012,489 B22011
- Replication-competent vesicular stomatitis viruses3US 9,861,668 B2Mayo Foundation for Medical Education and Research · 2018
- Replication-competent vesicular stomatitis viruses2US 9,555,067 B2Mayo Foundation for Medical Education and Research · 2017
- Replication-competent vesicular stomatitis viruses1US 10,610,553 B2Mayo Foundation for Medical Education and Research · 2020
- Oncolytic virus vaccine and drug for treating tumors by combining oncolytic virus vaccine with immune cells1US 12,496,337 B2Joint Biosciences (Sh) Ltd. · 2025